These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17299172)

  • 1. Study flaw in comparisons of aprepitant and ondansetron.
    Cavaretta M; Noviasky J
    Am J Health Syst Pharm; 2007 Feb; 64(4):350. PubMed ID: 17299172
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparisons of aprepitant and ondansetron.
    Carides A; Reiss T; Lines C; McKeon B; Diemunsch P
    Am J Health Syst Pharm; 2007 Dec; 64(23):2422-4; author reply 2424-6. PubMed ID: 18029945
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
    Gan TJ; Apfel CC; Kovac A; Philip BK; Singla N; Minkowitz H; Habib AS; Knighton J; Carides AD; Zhang H; Horgan KJ; Evans JK; Lawson FC;
    Anesth Analg; 2007 May; 104(5):1082-9, tables of contents. PubMed ID: 17456656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
    Diemunsch P; Gan TJ; Philip BK; Girao MJ; Eberhart L; Irwin MG; Pueyo J; Chelly JE; Carides AD; Reiss T; Evans JK; Lawson FC;
    Br J Anaesth; 2007 Aug; 99(2):202-11. PubMed ID: 17540667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery.
    Sinha AC; Singh PM; Williams NW; Ochroch EA; Goudra BG
    Obes Surg; 2014 Feb; 24(2):225-31. PubMed ID: 23990451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant: A New Modality for the Prevention of Postoperative Nausea and Vomiting: An Evidence-Based Review.
    Milnes V; Gonzalez A; Amos V
    J Perianesth Nurs; 2015 Oct; 30(5):406-17. PubMed ID: 26408515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
    Rapoport BL
    Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.
    Diemunsch P; Apfel C; Gan TJ; Candiotti K; Philip BK; Chelly J; Carides AD; Evans JK; Ho TW; Reiss T
    Curr Med Res Opin; 2007 Oct; 23(10):2559-65. PubMed ID: 17845742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant: A Novel Medicaton in the Prevention of Postoperative Nausea and Vomiting.
    Ritchie MK; Ellison M; Ranganathan P; Sizemore D; Vallejo MC
    W V Med J; 2016; 112(6):20-4. PubMed ID: 29368823
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
    Ades S; Halyard M; Wilson K; Ashikaga T; Heimann R; Kumar S; Blackstock W
    Support Care Cancer; 2017 May; 25(5):1503-1510. PubMed ID: 28032216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis.
    Singh PM; Borle A; Rewari V; Makkar JK; Trikha A; Sinha AC; Goudra B
    Postgrad Med J; 2016 Feb; 92(1084):87-98. PubMed ID: 26627976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
    Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
    Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
    Galy G; Labidi SI; Tissier F; Combes JD; Auger A; Favier B; Latour JF
    Bull Cancer; 2009 Feb; 96(2):141-5. PubMed ID: 19258220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study.
    Soga T; Kume K; Kakuta N; Hamaguchi E; Tsutsumi R; Kawanishi R; Fukuta K; Tanaka K; Tsutsumi YM
    J Anesth; 2015 Oct; 29(5):696-701. PubMed ID: 25801542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study.
    Kakuta N; Kume K; Hamaguchi E; Tsutsumi R; Mita N; Tanaka K; Tsutsumi YM
    J Anesth; 2015 Dec; 29(6):836-41. PubMed ID: 26210166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of postoperative nausea and vomiting with dolasetron versus ondansetron: is there a conflict of interest?
    White PF
    Anesth Analg; 2005 Dec; 101(6):1887. PubMed ID: 16301287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.